Microenterprise intervention to reduce sexual risk behaviors and increase employment and HIV preventive practices in economically-vulnerable African-American young adults (EMERGE): protocol for a feasibility randomized clinical trial.


Journal

Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253

Informations de publication

Date de publication:
17 Jul 2019
Historique:
received: 30 01 2019
accepted: 15 06 2019
entrez: 19 7 2019
pubmed: 19 7 2019
medline: 6 2 2020
Statut: epublish

Résumé

Economic vulnerability, such as homelessness and unemployment, contributes to the HIV risk among racial minorities in the U.S., who are disproportionately infected. Yet, few economic-strengthening interventions have been adapted for HIV prevention in economically-vulnerable African-American young adults. Engaging Microenterprise for Resource Generation and Health Empowerment (EMERGE) is a feasibility randomized clinical trial of an HIV prevention microenterprise intervention with integrated text messages ("nudges") that are informed by behavioral economic principles. The trial aims to reduce sexual risk behaviors and increase employment and uptake of HIV preventive behaviors. In total, 40 young adults who are African-American, aged 18-24, live in Baltimore City, have experienced at least one episode of homelessness in the last 12 months, are unemployed or underemployed (fewer than 10 h per week), are not enrolled in school, own a cell phone with text messaging, and report at least one episode of unprotected or unsafe sex in the prior 12 months will be recruited from two community-based organizations providing residential supportive services to urban youth. Participants will undergo a 3-week run-in period and thereafter be randomly assigned to one of two groups with active interventions for 20 weeks. The first group ("comparison") will receive text messages with information on job openings. The second group ("experimental") will receive text messages with information on job openings plus information on HIV prevention and business educational sessions, a mentored apprenticeship, and a start-up grant, and business and HIV prevention text messages based on principles from behavioral economics. The two primary outcomes relate to the feasibility of conducting a larger trial. Secondary outcomes relate to employment, sexual risk behaviors, and HIV preventive practices. All participants will be assessed using an in-person questionnaire at pre-intervention (prior to randomization) and at 3 weeks post-intervention. To obtain repeated, longitudinal measures, participants will be assessed weekly using text message surveys from pre-intervention up to 3 weeks post-intervention. This study will be one of the first U.S.-based feasibility randomized clinical trials of an HIV prevention microenterprise intervention for economically-vulnerable African-American young adults. The findings will inform whether and how to conduct a larger efficacy trial for HIV risk reduction in this population. ClinicalTrials.gov, NCT03766165 . Registered on 4 December 2018.

Sections du résumé

BACKGROUND BACKGROUND
Economic vulnerability, such as homelessness and unemployment, contributes to the HIV risk among racial minorities in the U.S., who are disproportionately infected. Yet, few economic-strengthening interventions have been adapted for HIV prevention in economically-vulnerable African-American young adults. Engaging Microenterprise for Resource Generation and Health Empowerment (EMERGE) is a feasibility randomized clinical trial of an HIV prevention microenterprise intervention with integrated text messages ("nudges") that are informed by behavioral economic principles. The trial aims to reduce sexual risk behaviors and increase employment and uptake of HIV preventive behaviors.
METHODS/DESIGN METHODS
In total, 40 young adults who are African-American, aged 18-24, live in Baltimore City, have experienced at least one episode of homelessness in the last 12 months, are unemployed or underemployed (fewer than 10 h per week), are not enrolled in school, own a cell phone with text messaging, and report at least one episode of unprotected or unsafe sex in the prior 12 months will be recruited from two community-based organizations providing residential supportive services to urban youth. Participants will undergo a 3-week run-in period and thereafter be randomly assigned to one of two groups with active interventions for 20 weeks. The first group ("comparison") will receive text messages with information on job openings. The second group ("experimental") will receive text messages with information on job openings plus information on HIV prevention and business educational sessions, a mentored apprenticeship, and a start-up grant, and business and HIV prevention text messages based on principles from behavioral economics. The two primary outcomes relate to the feasibility of conducting a larger trial. Secondary outcomes relate to employment, sexual risk behaviors, and HIV preventive practices. All participants will be assessed using an in-person questionnaire at pre-intervention (prior to randomization) and at 3 weeks post-intervention. To obtain repeated, longitudinal measures, participants will be assessed weekly using text message surveys from pre-intervention up to 3 weeks post-intervention.
DISCUSSION CONCLUSIONS
This study will be one of the first U.S.-based feasibility randomized clinical trials of an HIV prevention microenterprise intervention for economically-vulnerable African-American young adults. The findings will inform whether and how to conduct a larger efficacy trial for HIV risk reduction in this population.
TRIAL REGISTRATION BACKGROUND
ClinicalTrials.gov, NCT03766165 . Registered on 4 December 2018.

Identifiants

pubmed: 31315685
doi: 10.1186/s13063-019-3529-7
pii: 10.1186/s13063-019-3529-7
pmc: PMC6637550
doi:

Banques de données

ClinicalTrials.gov
['NCT03766165']

Types de publication

Clinical Trial Protocol Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

439

Subventions

Organisme : NICHD NIH HHS
ID : R25 HD045810
Pays : United States
Organisme : NIMH NIH HHS
ID : R25 MH067127
Pays : United States
Organisme : NIMH NIH HHS
ID : K01MH107310
Pays : United States

Références

J Eval Clin Pract. 2004 May;10(2):307-12
pubmed: 15189396
AIDS Care. 2006 Jan;18(1):1-11
pubmed: 16282070
AIDS Care. 2007;19 Suppl 1:S23-4
pubmed: 17364384
AIDS. 2007 Nov;21 Suppl 7:S49-56
pubmed: 18040164
AIDS. 2008 Aug 20;22(13):1659-65
pubmed: 18670227
MMWR Morb Mortal Wkly Rep. 2008 Oct 3;57(39):1073-6
pubmed: 18830210
AIDS Behav. 2009 Jun;13(3):449-61
pubmed: 18998204
Am J Prev Med. 2009 May;36(5):452-7
pubmed: 19362699
Health Educ Behav. 2010 Jun;37(3):343-56
pubmed: 19887626
Bull World Health Organ. 2009 Nov;87(11):824-32
pubmed: 20072767
Am J Public Health. 2010 Mar;100(3):483-8
pubmed: 20075323
J Adolesc Health. 2010 Apr;46(4):372-8
pubmed: 20307827
AIDS Behav. 2010 Jun;14(3):649-57
pubmed: 20352320
BMC Med Res Methodol. 2010 Jul 16;10:67
pubmed: 20637084
Lancet. 2010 Nov 27;376(9755):1838-45
pubmed: 21071074
AIDS Behav. 2011 Jul;15(5):911-8
pubmed: 21153762
Drug Alcohol Depend. 2012 Jun 1;123(1-3):15-21
pubmed: 22055012
J Clin Epidemiol. 2012 Mar;65(3):301-8
pubmed: 22169081
AIDS Care. 2014 Feb;26(2):152-9
pubmed: 23767788
AIDS Behav. 2013 Nov;17(9):2864-77
pubmed: 23963497
J Urban Health. 2014 Oct;91(5):836-50
pubmed: 25135594
Drug Alcohol Depend. 2014 Nov 1;144:53-60
pubmed: 25190049
PLoS One. 2014 Nov 21;9(11):e113621
pubmed: 25415455
Exp Clin Psychopharmacol. 2015 Feb;23(1):49-58
pubmed: 25545764
J Acquir Immune Defic Syndr. 2015 Apr 1;68(4):e61-3
pubmed: 25559597
AIDS Behav. 2015 Jun;19 Suppl 2:130-41
pubmed: 25563501
JMIR Mhealth Uhealth. 2015 Apr 13;3(2):e34
pubmed: 25872754
Soc Sci Med. 2015 May;133:177-88
pubmed: 25875324
AIDS Behav. 2015 Nov;19(11):2069-75
pubmed: 25987190
Prev Sci. 2016 Jan;17(1):134-43
pubmed: 26228480
AIDS Behav. 2016 May;20(5):1049-59
pubmed: 26362167
J Sex Res. 2016;53(3):331-45
pubmed: 26421980
Stroke. 2015 Dec;46(12):3370-4
pubmed: 26508753
Glob Public Health. 2016 Dec;11(10):1202-1215
pubmed: 26588115
J Acquir Immune Defic Syndr. 2016 Jun 1;72(2):e50-2
pubmed: 26918543
PLoS One. 2016 Mar 15;11(3):e0150205
pubmed: 26978655
J Health Commun. 2016 Jul;21(7):725-33
pubmed: 27232544
Circ Heart Fail. 2016 Jun;9(6):
pubmed: 27296397
Am Indian Alsk Native Ment Health Res. 2016;23(3):248-70
pubmed: 27383095
Trials. 2016 Jul 29;17:374
pubmed: 27474021
BMJ. 2016 Oct 24;355:i5239
pubmed: 27777223
BMC Int Health Hum Rights. 2016 Oct 28;16(1):27
pubmed: 27793147
AIDS Behav. 2017 Sep;21(9):2784-2798
pubmed: 28078495
Eur Respir J. 2017 Jun 22;49(6):
pubmed: 28642311
J Card Fail. 2017 Sep;23(9):700-701
pubmed: 28757151
Trials. 2018 Feb 17;19(1):112
pubmed: 29452599
Pilot Feasibility Stud. 2018 Jul 4;4:97
pubmed: 29997904
Trials. 2018 Jul 31;19(1):406
pubmed: 30060763
Trials. 2018 Aug 29;19(1):461
pubmed: 30157920
AIDS Care. 2018 Jan - Dec;30(sup1):37-43
pubmed: 30235937
Trials. 2018 Dec 11;19(1):676
pubmed: 30537982

Auteurs

Larissa Jennings Mayo-Wilson (LJ)

Department of International Health, Social and Behavioral Interventions Program, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street, Room E5038, Baltimore, MD, 21205, USA. ljennin6@jhu.edu.
Department of Applied Health Science, Indiana University School of Public Health, 1025 E. 7th Street, Bloomington, IN, USA. ljennin6@jhu.edu.

Nancy E Glass (NE)

Johns Hopkins University School of Nursing, 525 N. Wolfe Street, Baltimore, MD, USA.

Fred M Ssewamala (FM)

Washington University in St. Louis, The Brown School, Goldfarb, One Brookings, Drive, St. Louis, MO, USA.

Sebastian Linnemayr (S)

RAND Corporation, 1776 Main Street, Santa Monica, CA, USA.

Jessica Coleman (J)

Department of International Health, Social and Behavioral Interventions Program, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street, Room E5038, Baltimore, MD, 21205, USA.

Fatmata Timbo (F)

Department of International Health, Social and Behavioral Interventions Program, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street, Room E5038, Baltimore, MD, 21205, USA.

Matthew W Johnson (MW)

Behavioral Pharmacology Research, Johns Hopkins University School of Medicine, 5510 Nathan Shock Drive, Baltimore, MD, USA.

Melissa Davoust (M)

Department of International Health, Social and Behavioral Interventions Program, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street, Room E5038, Baltimore, MD, 21205, USA.

Alain Labrique (A)

Department of International Health, Social and Behavioral Interventions Program, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street, Room E5038, Baltimore, MD, 21205, USA.

Gayane Yenokyan (G)

Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, 615 N. Wolfe Street, Baltimore, MD, USA.

Brian Dodge (B)

Department of Applied Health Science, Indiana University School of Public Health, 1025 E. 7th Street, Bloomington, IN, USA.

Carl Latkin (C)

Department of Health, Behavior and Society, Johns Hopkins Bloomberg School of Public Health, 624 N Broadway, Hampton House 737, Baltimore, MD, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH